CompletedNot Applicable

The Effect of Electrostimulation and Compression Applications on Neuropathy Symptoms and Quality of Life in the Management of Chemotherapy-Induced Peripheral Neuropathy in Gastrointestinal System Cancer Patients Receiving Oxaliplatin-Based Treatment

Turkey (Türkiye)140 participantsStarted 2025-01-02

Plain-language summary

This research was conducted to evaluate the effect of electrostimulation and compression applications on the severity, number, and pain levels of neuropathy symptoms and the quality of life of patients with metastatic gastrointestinal cancer receiving oxaliplatin-based treatment in the management of chemotherapy-induced peripheral neuropathy. The study population consisted of patients with gastrointestinal cancer between 2025-2026 . Data collection tools were administered to patients who met the inclusion criteria and developed chemotherapy-induced peripheral neuropathy. Patients were then stratified by age and gender and assigned to "control group, electrostimulation group, compression group, and electrostimulation+compression group" using block randomization. Statistical power analysis determined the total number of participants in the study as 140 patients, with 35 patients in each group. Patients in the control group benefited from the clinic's standard procedures and received no intervention

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Being 18 years of age or older, * Having a diagnosis of metastatic gastrointestinal cancer (stomach, pancreas, colon, rectum), * Being scheduled to receive 6 cycles of chemotherapy, * Having received 1 cycle of oxaliplatin-based chemotherapy (FOLFOX and FOLFİRİNOX), * Not having a diagnosed mental disorder, * Not having skin problems in the areas where TENS and compression applications will be performed, * Having verbally and in writing approved the informed consent form after being informed and explained about the study. Exclusion Criteria: * Having previously received oxaliplatin-based treatment (monotherapy or combination), * Having a pacemaker, * Having a history of any skin sensitivity in the hands and feet, * Having received or currently receiving another neurotoxic chemotherapy agent other than oxaliplatin-based treatment, * Having developed peripheral neuropathy due to reasons other than chemotherapy \[tumor compression, nutritional deficiencies, infections, or major systemic disease (diabetes mellitus, etc.)\].

What they're measuring

EORTC QLQ-C30 Quality of Life Scale

Timeframe: 10 weeks

Trial details

NCT IDNCT07409987

SponsorCumhuriyet University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-02-28